Chlamydia Trachomatis Infection

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Evofem Biosciences
Evofem BiosciencesCA - San Diego
1 program
1
EVO100Phase 2/31 trial
Active Trials
NCT03107377CompletedEst. Aug 2019
Abbott
AbbottABBOTT PARK, IL
1 program
ID NOW™N/A1 trial
Active Trials
NCT06395675Not Yet Recruiting7,100Est. Jan 2025
Roche
RocheSTAVANGER NORWAY, Norway
1 program
cobas® liat CT/NG/MG nucleic acid testN/A1 trial
Active Trials
NCT06369220Completed344Est. May 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Evofem BiosciencesEVO100
Rochecobas® liat CT/NG/MG nucleic acid test
AbbottID NOW™

Clinical Trials (3)

Total enrollment: 7,444 patients across 3 trials

NCT03107377Evofem BiosciencesEVO100

Phase 2B/3 Double-blinded Placebo-controlled

Start: Nov 2017Est. completion: Aug 2019
Phase 2/3Completed
NCT06369220Rochecobas® liat CT/NG/MG nucleic acid test

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

Start: Jul 2024Est. completion: May 2025344 patients
N/ACompleted
NCT06395675AbbottID NOW™

Clinical Evaluation of the ID NOW™ CT/NG Test

Start: Jul 2024Est. completion: Jan 20257,100 patients
N/ANot Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space